Human Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Human Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
The trust cornerstone of PeptideVox — how we assign an A-to-D evidence grade to every peptide claim, anchored to GRADE, the Oxford CEBM levels, USPSTF, and Cochrane RoB 2, and why human evidence is never blended with animal, in-vitro, or anecdotal data.
A cross-sex, evidence-first overview of the peptides studied for sexual desire, arousal and erectile function — bremelanotide, kisspeptin, melanotan II and oxytocin — graded honestly for men and women. Only one is FDA-approved.
A clinical-editorial ranking of the peptides studied for low sexual desire in women — bremelanotide (PT-141/Vyleesi), kisspeptin and oxytocin — graded honestly. Only one is FDA-approved, and even that is a modest, as-needed tool.
A clinical-editorial ranking of the peptides studied for male low libido — PT-141, kisspeptin and gonadorelin — graded honestly. The strongest evidence for male desire is correcting low testosterone, not a peptide.
A clinical, evidence-first review of the thymic peptides marketed for recurrent infections — thymosin alpha-1, thymalin, thymulin and thymogen. The honest headline: no peptide has an RCT showing it prevents everyday colds.
The honest fertility-peptide record: the strongest evidence belongs to the prescription reproductive hormones already in every IVF clinic — hCG, gonadotropins, gonadorelin — plus one investigational frontier, kisspeptin. No over-the-counter research peptide has human fertility data.
A clinical-editorial ranking of the peptides studied for erectile dysfunction — melanocortin agents (PT-141, melanotan-2) and kisspeptin — graded honestly against the AUA first-line standard. No peptide is FDA-approved for ED.
A clinical monograph on sermorelin — the GHRH(1-29) growth-hormone secretagogue once FDA-approved for diagnosis and pediatric GH deficiency. Real but modest, mostly pre-2000 human trials; the anti-aging marketing outruns the data.
A clinical monograph on examorelin — the International Nonproprietary Name for hexarelin, a synthetic hexapeptide growth-hormone secretagogue. Small human pharmacodynamic trials (Grade B), never approved, and WADA-prohibited at all times.
A clinical monograph on Semax — the Russian-developed ACTH(4-10) heptapeptide used intranasally for stroke recovery and cognition. Real but single-country human data, graded B, with an unsettled 2026 FDA status.
A clinical monograph on Melanotan II (MT-II) — the non-selective melanocortin agonist sold illegally for tanning. Thin 1990s human data, a high-risk safety profile, and an unapproved 2026 legal status.
A clinical monograph on palmitoyl tripeptide-38 (Matrixyl Synthe'6) — the topical matrikine marketed to rebuild six matrix proteins. Real but low-tier, manufacturer-led human data, no independent RCT.
A clinical monograph on Kisspeptin-10 (KP-10), the KISS1R/GPR54 agonist that drives the reproductive axis. Robust human physiology data, no Grade-A outcome RCT, and a 2026 legal status that is not-approved, non-compoundable and banned in sport.
A clinical monograph on ipamorelin — the selective growth-hormone secretagogue famous for the CJC-1295 stack. One human PD study, one failed RCT, and an unsettled 2026 legal status.
A clinical monograph on gonadorelin — synthetic native GnRH used as an HPG-axis diagnostic and as pulsatile pump therapy. Real human efficacy in narrow indications, but the popular TRT-adjunct use is essentially unstudied.
A clinical monograph on GHRP-6 — the first-generation ghrelin-receptor agonist that reliably triggers a growth hormone pulse and a potent appetite surge. Real but small human data, no therapeutic RCTs, and a restricted 2026 legal status.
A clinical monograph on GHRP-2 (pralmorelin) — the ghrelin-receptor agonist approved in Japan as a single-dose GH-deficiency diagnostic. Grade-A acute GH provocation, no chronic-use evidence, and a restrictive 2026 legal status.
A clinical monograph on GHK-Cu (copper tripeptide-1) — the endogenous copper-binding peptide with genuine topical human data for skin and wound healing, and a speculative injectable story with no controlled human evidence.
A clinical monograph on Biotinoyl Tripeptide-1 — the biotinylated GHK matrikine peptide behind Procapil. Modest, consistent hair-density benefits in combination formulations, but no isolated-molecule human trial.
A clinical monograph on epithalamin — the bovine pineal-gland peptide extract that is the natural precursor of synthetic epitalon. A provocative single-program human mortality dataset, no independent RCT, and an unsettled 2026 legal status.
Human Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Human Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.